Shun Nakazawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shun Nakazawa has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Kazuhisa Takahashi
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
2 shared publications- Motoyasu Kato
Department of Respiratory Medicine Juntendo University Graduate School of Medicine Tokyo Japan
2 shared publications - Shinsaku Togo
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
2 shared publications Shouichi Okamoto
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
2 shared publicationsYuriko Terayama
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
2 shared publicationsChisato Tadokoro
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
Aged garlic extract suppressed macrophage-mediated inflammation in acute respiratory distress syndrome
Combining aged garlic extract (AGE) with low-dose dexamethasone broadens and enhances the suppression of pulmonary inflammation in ARDS by inhibiting NF-κB signaling, offering a potent therapeutic approach with reduced steroid side effects.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
Open AccessAged garlic extract suppressed macrophage-mediated inflammation in acute respiratory distress syndrome
Combining aged garlic extract (AGE) with low-dose dexamethasone broadens and enhances the suppression of pulmonary inflammation in ARDS by inhibiting NF-κB signaling, offering a potent therapeutic approach with reduced steroid side effects.
- Open Access
- 1 February 2024
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 17, 101-104
Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report
We report a case of a 62-year-old male who was diagnosed with advanced rectal cancer. The attending gastro-enterologist initiated chemotherapy using capecitabine plus oxaliplatin and bevacizumab; however, this treatment regimen was discontinued, as the patient developed a skin rash. Once the skin rash improved, chemotherapy was re-initiated using a combination of trifluridine and tipiracil hydrochloride (TAS-102). The patient developed high fever and dyspnea 2 months after initiation of TAS-102. Chest high-resolution computed tomography showed bilateral diffuse ground glass opacities in all lung lobes with traction bronchiectasis. At this time, the gastro-enterologist consulted our department. The patient was put on non-invasive positive pressure ventilation due to worsening respiratory symptoms. The patient was suspected to develop TAS-102-induced interstitial pneumonia based on positive TAS-102 drug-induced lymphocyte stimulation test. The patient’s respiratory symptoms and radiological findings improved after corticosteroid treatment. The corticosteroid dose was gradually decreased by 5 mg. Thereafter, chemotherapy was re-initiated using different anti-cancer agents.
- 1 February 2024
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 17, 101-104
Open AccessTrifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report
We report a case of a 62-year-old male who was diagnosed with advanced rectal cancer. The attending gastro-enterologist initiated chemotherapy using capecitabine plus oxaliplatin and bevacizumab; however, this treatment regimen was discontinued, as the patient developed a skin rash. Once the skin rash improved, chemotherapy was re-initiated using a combination of trifluridine and tipiracil hydrochloride (TAS-102). The patient developed high fever and dyspnea 2 months after initiation of TAS-102. Chest high-resolution computed tomography showed bilateral diffuse ground glass opacities in all lung lobes with traction bronchiectasis. At this time, the gastro-enterologist consulted our department. The patient was put on non-invasive positive pressure ventilation due to worsening respiratory symptoms. The patient was suspected to develop TAS-102-induced interstitial pneumonia based on positive TAS-102 drug-induced lymphocyte stimulation test. The patient’s respiratory symptoms and radiological findings improved after corticosteroid treatment. The corticosteroid dose was gradually decreased by 5 mg. Thereafter, chemotherapy was re-initiated using different anti-cancer agents.
- Open Access
- 30 January 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (3) , e01085
Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
Key message: This is the first case confirmed the association between PI development and nintedanib by the reproducibility of PI development. In patients taking a combination treatment with corticosteroid and nintedanib, clinicians should be careful regarding the development of PI although the patient improved only after discontinuation of nintedanib treatment.
- 30 January 2023
- Published by Wiley in Respirology Case Reports
- Vol. 11 (3) , e01085
Open AccessPneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
Key message: This is the first case confirmed the association between PI development and nintedanib by the reproducibility of PI development. In patients taking a combination treatment with corticosteroid and nintedanib, clinicians should be careful regarding the development of PI although the patient improved only after discontinuation of nintedanib treatment.
- Open Access
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1904
Efficacy and Tolerability of Low-Dose Nintedanib for Idiopathic Pulmonary Fibrosis in the Real World
- 3 May 2021
- Published by Oxford University Press (OUP)
- p. A1904
Open AccessEfficacy and Tolerability of Low-Dose Nintedanib for Idiopathic Pulmonary Fibrosis in the Real World